Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Schwingenschuh, P; Katschnig, P; Jehna, M; Koegl-Wallner, M; Seiler, S; Wenzel, K; Ropele, S; Langkammer, C; Gattringer, T; Svehlík, M; Ott, E; Fazekas, F; Schmidt, R; Enzinger, C.
Levodopa changes brain motor network function during ankle movements in Parkinson's disease.
J Neural Transm. 2013; 120(3):423-433 Doi: 10.1007/s00702-012-0896-6
Web of Science PubMed FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Enzinger Christian
Katschnig-Winter Petra
Schwingenschuh Petra
Co-Autor*innen der Med Uni Graz
Fazekas Franz
Gattringer Thomas
Jehna Margit
Langkammer Christian
Ropele Stefan
Schmidt Reinhold
Seiler Stephan
Svehlik Martin
Wenzel Karoline

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Bradykinesia-the cardinal symptom in Parkinson's disease (PD)-affects both upper and lower limbs. While several functional imaging studies investigated the impact of levodopa on movement-related neural activity in Parkinson's disease during upper limb movements, analogue studies on lower limb movements are rare. We studied 20 patients with PD (mean age 66.8 ± 7.2 years) after at least 12 h drug withdrawal (OFF-state) and a second time approximately 40 min after oral administration of 200 mg levodopa (ON-state) behaviourally and by functional magnetic resonance imaging (fMRI) at 3 T during externally cued active ankle movements of the more affected foot at fixed rate. Results were compared with that obtained in ten healthy controls (HC) to separate pure pharmacological from disease-related levodopa-induced effects and to allow for interaction analyses. Behaviourally, all patients improved by at least 20 % regarding the motor score of the Unified Parkinson's disease rating scale after levodopa-challenge (mean scores OFF-state: 38.4 ± 10.1; ON-state: 25.5 ± 8.1). On fMRI, levodopa application elicited increased activity in subcortical structures (contralateral putamen and thalamus) in the patients. In contrast, no significant levodopa-induced activation changes were found in HC. The interaction between "PD/HC group factor" and "levodopa OFF/ON" did not show significant results. Given the levodopa-induced activation increases in the putamen and thalamus with unilateral ankle movements in patients with PD but not in HC, we speculate that these regions show the most prominent response to levodopa within the cortico-subcortical motor-circuit in the context of nigrostriatal dysfunction.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Ankle - innervation
Antiparkinson Agents - therapeutic use
Brain Mapping -
Female -
Humans -
Levodopa - therapeutic use
Magnetic Resonance Imaging -
Male -
Middle Aged -
Movement - drug effects
Parkinson Disease - drug therapy
Putamen - drug effects
Thalamus - drug effects

Find related publications in this database (Keywords)
Parkinson's disease
Motor control
Ankle movements
Levodopa challenge
© Med Uni Graz Impressum